NCT03319498

Brief Summary

The purpose of this study is to examine the effectiveness of peppermint oil to promote voiding and reduce urinary catheterization among postpartum women.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 18, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 24, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 16, 2026

Completed
Last Updated

March 5, 2026

Status Verified

March 1, 2026

Enrollment Period

8.1 years

First QC Date

October 18, 2017

Last Update Submit

March 3, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Resolution of Postpartum Urinary Retention

    Spontaneous bladder voiding of at least 150 milliliters

    within 10 minutes after administering study intervention

Secondary Outcomes (3)

  • Time to resolution of urinary retention

    Within 6 hours of postpartum urinary retention

  • Volume of urine voided

    Within 6 hours of postpartum urinary retention

  • Patient Satisfaction Level

    Within one hour of study intervention administration

Study Arms (2)

Peppermint Oil Vapor

ACTIVE COMPARATOR

Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.

Other: Peppermint Oil Vapor

Mineral Oil Vapor

PLACEBO COMPARATOR

Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.

Other: Mineral Oil Vapor

Interventions

2ml of the oil will be placed in the urine collection "hat" that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.

Peppermint Oil Vapor

2ml of the mineral oil will be placed in the urine collection "hat" that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.

Mineral Oil Vapor

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsStudy participants are postpartum women with urinary retention.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • postpartum patients at Mount Carmel East, Mount Carmel West, and Mount Carmel St. Ann's Hospital
  • years or older
  • able to read and understand English
  • unable to spontaneously void within 6 hours after vaginal delivery or within 6 hours after straight catheter or within 6 hours after catheter removal for cesarean delivery.

You may not qualify if:

  • patients who have an allergy to peppermint oil
  • patients who have asthma
  • patients who report sensitivity to smells
  • patients who have a clinical condition which precludes walking/use of standard toilet

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mount Carmel Health System

Columbus, Ohio, 43232, United States

Location

MeSH Terms

Conditions

Urinary Retention

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Robin L Driver, BS

    Mount Carmel Health System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized Controlled Trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 18, 2017

First Posted

October 24, 2017

Study Start

January 1, 2018

Primary Completion

February 16, 2026

Study Completion

February 16, 2026

Last Updated

March 5, 2026

Record last verified: 2026-03

Locations